Income Statement Presentation 2023

Roche STRONG-HF1 trial stopped early due to superior efficacy² Significant reduction of hospitalizations or mortality in heart failure Evaluate the efficacy and safety of rapid up-titration of oral HF therapy, supported by Disease burden > 64m patients diagnosed with heart failure annually5 NT-proBNP monitoring2,3,4 >50% mortality after 5 years of patients under current site of care treatment regimen STRONG-HF CONTEMPORARY POST-DISCHARGE MANAGEMENT IN HEART FAILURE Study set up FQ American Heart Association. 6 tests per patient of NT-proBNP are needed for safety monitoring (on label) Serial measurements of NT-proBNP during uptitration of 4 evidence based HF drugs? N=1078 Pts8, 10EP: composite all-cause death + HF hospitalization at day 180 Outcome: 34% decrease in hospitalization and deaths, p<0.05 (NNT=12)2,9 1 Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testing, of Heart Failure Therapies; 2 Mebazza-A et al. Lancet 2022. 400:1938-1952; 3 Kimmoun-A et al. Eur J Heart Fail 2019. 21: 1459-1467; 4 Gotter-G et 44 al. Eur J Heart Fail 2021. 23:1981-1982; 5 Groenewegen-A et al. Eur J Heart Fail 2020. 22:1342-1356; 'multicenter, randomized, parallel group strategy-based trial; 7 Source: https://clinicaltrials.gov/ct2/show/NCT03412201, Drugs: beta-blockers; angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blocker (ARB) or angiotensin receptor neprolysin inhibitor (ARNI); and mineralocorticoid receptor antagonist (MRAs); 8 Initially planned study setup of n=1,800 which wasn't reached due to termination for superior efficacy; 9 NNT = Number Needed to Treat

View entire presentation